Peptide therapies
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
October 23, 2026Diabetes, Obesity, Peptide therapies, clinical trials, diabetes, weight reduction
Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose than oral semaglutide in adults …
Japanese pharma outsources earlier as peptide development challenges grow
April 29, 2026Peptide therapies, peptide
Japanese pharmaceutical companies are increasingly engaging contract development and manufacturing organisations (CDMOs) earlier in the drug development process, as the …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
